Decentralized Trials
Traditional clinical trial designs required participants to visit healthcare or research facilities for assessments. In contrast, decentralized clinical trials (DCTs) reduce the need for in-clinic visits by utilizing telemedicine, electronic tools, remote assessments, and wearable devices to collect data. Essentially, while traditional study designs require patients to come to clinics, DCTs allow the “clinic” to reach the patients. The advantages of DCTs, made possible by current technologies, are significant, thus allowing us to engage with patients in their natural environments, which minimizes the burden of participation in studies. Concerns that existed about data integrity have shifted to a recognition that high-quality data can be collected remotely, often in greater volumes than what was feasible with traditional designs. Furthermore, we can now also connect with physician investigators from various locations, as telemedicine has become widely adopted.
Clinilabs conducts DCTs using top-tier technology tools from our own data systems as well as third-party vendors. What sets us apart from other contract research organizations (CROs) is our expertise in identifying the best tools for specific tasks and ensuring the seamless integration of data systems. This comprehensive integration produces added value when carrying out DCTs.
Click below to learn how Clinilabs’ designed a decentralized trial at the onset of the COVID-19 pandemic.
Without drugs, physicians would struggle to find relevance, and patients would suffer without hope.
It is easy to get a thousand prescriptions, but hard to get one single remedy.
There is so much more to be done; the patients are waiting.
The reward for work well done is the opportunity to do more.
The best way to predict the future is to invent it.
The pace of discovery is going unbelievably fast.
The greatest joy in life is to accomplish. It is the getting, not the having. It is the giving, not the keeping.
If you think compliance is expensive, try non-compliance.
I trust I may be enabled in the treatment of patients always to act with a single eye to their good.
Good information is the best medicine.
Remember the Three Princes of Serendip who went out looking for treasure? They didn’t find what they were looking for, but they kept finding things just as valuable. That’s serendipity, and our business [drugs] is full of it.
All truths are easy to understand once they are discovered; the point is to discover them.
Drugs don’t work in patients who don’t take them.
I am not accustomed to saying anything with certainty after only one or two observations.
One sometimes finds what one is not looking for.
I have no ideology. My ideology is health.
One never notices what has been done; one can only see what remains to be done.
The cures we want aren’t going to fall from the sky. We have to get ladders and climb up and get them.
Advances in drug development have led to greater improvement in the quality of human life than advances in all other fields combined.
Let me tell you the secret that has led me to my goal. My strength lies solely in my tenacity.
I must say, I spend a lot of my time these days trying to persuade people that controlled trials are the only way to get information that’s reliable about drugs.